Childhood IgA nephropathy (cIgAN) differs from the adult by having an abrupt clinical onset, often presenting as an acute attack that can progress to a chronic phase. No treatment guidelines have been established for the treatment of cIgAN. Given the severity of acute attack in children, and the number of life-years at stake, pediatricians prescribe immunosuppression in addition to renin-angiotensin system blockade. Non-specific immunosuppressors, such as corticosteroids, have systemic toxic effects, and given recent therapeutic advances in adult glomerulonephritis, new tailored strategies should be expected for children. The mucosal immune system has been highlighted as a key player in IgAN pathogenesis, and several biomarkers have been identified with a direct role in pathogenesis. In this review, we discuss current studies of conventional and novel therapeutic approaches for cIgAN.

中文翻译：

---

儿童 IgA 肾病的新治疗前景。

儿童 IgA 肾病 (cIgAN) 与成人的不同之处在于临床发病突然，通常表现为急性发作，可进展为慢性期。没有针对 cIgAN 的治疗制定治疗指南。考虑到儿童急性发作的严重性，以及危及生命年数，除了肾素-血管紧张素系统阻滞剂外，儿科医生还开出免疫抑制剂的处方。非特异性免疫抑制剂，如皮质类固醇，具有全身毒性作用，鉴于最近成人肾小球肾炎的治疗进展，应该期待针对儿童的新策略。粘膜免疫系统已被强调为 IgAN 发病机制的关键参与者，并且已经确定了几种在发病机制中具有直接作用的生物标志物。在这次审查中，